- As part of the agreement terms, UAB has received a non-exclusive licence to leverage the H2L2 Harbour Mice platform of Nona Biosciences for the creation of fully human The post Nona Biosciences partners with UAB to advance B Cell...
- Investors for the funding round include Johnson & Johnson Innovation, Deerfield Management, Catalio Capital Management, Braidwell, the Retinal Degeneration Fund, and GV. The company is dedicated to advancing The post Perceive Pharma...
- Following its recent US Food and Drug Administration (FDA) approval, the therapy is now a treatment option for patients aged two years and older with neurofibromatosis type 1 The post SpringWorks Therapeutics selects Onco360 as pharmacy...
- Romvimza is indicated for use in TGCT patients for whom surgery could worsen functional limitations or cause severe morbidity. The approval is based on the results from the The post US FDA approves Deciphera’s Romvimza for TGCT...
- This marks Epkinly as the first subcutaneously administered T-cell engaging bispecific antibody approved in the country for R/R follicular lymphoma as well as R/R large B-cell lymphomas. The The post Genmab’s epcoritamab gains...
- Roche (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is...
- For the average person, living at high altitude - where oxygen is sparser than at sea level - can have health benefits ranging from lower rates of heart disease to increased endurance. But for those born with inherited mitochondrial...
- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that investigational gene therapy AB-1005 for the treatment of Parkinson's disease (PD) has been granted...
- A research team co-led by scientists at the University of Arizona College of Medicine - Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease. The results were published today in...
- Scientists at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have developed a ground-breaking technique to deliver therapeutic molecules directly to the brain, bypassing the blood-brain barrier. Led...
- It also focuses on developing the candidate targeting other autoimmune disorders like Lupus Nephritis (LN). The partnership underscores Conduit’s commitment to creating high-quality preclinical data, which will play The post Conduit and...
- As part of this collaboration, Boehringer will utilise ExpressionEdits’ AI-powered platform, Genetic Syntax Engine, designed to boost gene expression without altering the genetic sequence, for the development of The post...
- When a tumour develops, it creates a structure around itself called the tumour stroma, within which blood and lymphatic vessels ensure nutritional and respiratory biological exchanges. Lymphangiogenesis, i.e. the development of lymphatic...
- Physical activity is not only important for fitness, but also for health. This is confirmed by a new study conducted under the direction of Prof. Dr. Maximilian Kleinert at the German Institute of Human Nutrition Potsdam-Rehbrücke...
- Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and The post FDA to review Regeneron’s linvoseltamab BLA for multiple...
- Antibiotics are indispensable for treating bacterial infections. But why are they sometimes ineffective, even when the bacteria are not resistant? In their latest study published in the journal Nature, researchers from the University of...
- The partnership will utilise the Pb-212 production technology and radionuclide development infrastructure of AdvanCell alongside Lilly’s expertise in drug development and drug candidate programmes. It will support the The post...
- In March last year, Fennec Pharmaceuticals entered an exclusive licensing agreement, granting Norgine commercialisation rights for the injection in Australia, New Zealand, and Europe. Under this agreement, Fennec The post Norgine...
- Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of a simple, minimally invasive Targeted Thermal Therapy (Triple T) that has the potential to transform medical...
- An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found. Results published in the Journal of Crohn's and Colitis revealed that an antibiotic called...
- After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare disease has an especially poor...
- Tuberculosis is a serious global health threat that infected more than 10 million people in 2022. Spread through the air and into the lungs, the pathogen that causes "TB" can lead to chronic cough, chest pains, fatigue, fever and weight...
- Many people would like to delay or even stop the aging process. Previous clinical studies have shown that a reduced calorie intake can slow down the aging process in humans. Taking vitamin D or omega-3 fatty acids has also shown...
- Secondary prevention medications for cardiovascular diseases (CVD) are underused globally and additional strategies to increase their use are needed to improve CVD management and reduce premature mortality rates, according to study...
- For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week. "It's been a tremendous success and has proven to be...
- Antibiotic resistance is a global public health crisis responsible for more than a million deaths annually. By 2050, the World Health Organization estimates it could surpass cancer and heart disease as the leading cause of death as more...
- Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, capable of binding and destroying previously undruggable disease-causing proteins. Inspired by OpenAI’s image...
- A natural compound derived from gut-friendly bacteria significantly slows the progression of vitiligo and may restore pigmentation, reports a new Northwestern University pre-clinical study in mice. The findings could offer hope to...
- Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face. Locally advanced tumours in particular can be difficult to treat surgically. A research team from MedUni Vienna and...
- A collaborative study between researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and the Institute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22